Table 1.

Patients whose paraneoplastic neurological autoimmunity was precipitated or exacerbated by innate immune system challenge.

Patient No. Sex/Age (yrs)	Cancer	Challenge	Neurological symptoms	Interval (weeks after challenge)	Neural IgG auto antibodies detected	CSF findings	Tobacco use (pack years)	Immunotherapy	Follow-up years (status)
1. M/68	Bladder and prostate (urothelial); skin (basal cell, squamous cell, melanoma)	BCG; tick bite	Cerebellar ataxia	4	CRMP5	13 WBC (88% lymphocytes), protein 80 mg/dL, OCB positive	20	None	24 (died 91 y.o.)
2. M/72	Bladder (urothelial)	BCG	Sensorimotor neuropathy, chorea	2	ANNA-1, CRMP5	Normal	22	IVMP, cyclophos-phamide	2 (alive)
3. F/39	Ovary	Extracts of “bacteria, thymus, spleen and liver”; TNF-α	Cerebellar ataxia	1	PCA-1	Not available	0	Plasmapheresis,	2 (alive)
4. F/74	Carcinoid (metastasis)	Tick bite, Babesia	Encephalopathy	3	VGKC, VGCC-P/Q, VGCC-N, CRMP5, GAD65, AChR, Striational	7 WBC (88% lymphocytes), protein normal, no OCB	0	IVMP	7 (dead)

ANNA-1, anti-neuronal nuclear antibody, type 1 (aka “anti-Hu”); BCG, bacillus Calmette-Guerin; Ca, carcinoma; CRMP5, collapsin response-mediator protein-5; GAD65, glutamic acid decarboxylase-65 kDa; IVMP, intravenous methylprednisolone; AChR, nicotinic muscle acetylcholine receptor; OCB, supernumerary oligoclonal bands; PCA-1, purkinje cell cytoplasmic antibody, type 1 (aka “anti-Yo”); TNF-α, tumor necrosis factor-α; VGCC, voltage-gated calcium channel; VGKC, voltage-gated (Kv1) potassium channel-complex (not subtyped for LGI1 or CASPR2 specificities); WBC, white blood cells.